SBRA vs WELL Stock Comparison
Compare SBRA and WELL across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between SBRA and WELL?
SBRA leads the current stock comparison as Sabra Health Care REIT, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Sabra Health Care REIT, Inc. vs Welltower Inc.
SBRA leads
SBRA leads by 10 AIQ points, primarily on Momentum and Risk Resilience, and the lead has widened from 3 points over 30 sessions.
Competitive: 3 of 6 evidence groups support SBRA, its lead is widening, and its signal state is cleanly positive.
Sabra Health Care REIT, Inc.
Welltower Inc.
The Algovestiq AIQ Score currently favors SBRA over WELL, 51 versus 41 as of Sep 11, 2026. SBRA's advantage is driven primarily by stronger momentum and risk resilience. SBRA also shows the stronger technical structure relative to its 50-day moving average. 3 of 6 covered evidence groups favor SBRA today, and the comparison is rated Competitive on stability: only 3 of 6 covered evidence groups agree. SBRA lead: Strengthening — the AIQ differential moved from 3 to 10 points over 30 sessions. SBRA leads on all four AIQ factor dimensions. Value is itself one of those four, so a sweep is not explained by valuation alone — it deserves additional scrutiny for unmodeled catalysts, expectations or event risk.
Compare Sabra Health Care REIT, Inc. and Welltower Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare SBRA and WELL against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum67 vs 44SBRA +23
- Risk Resilience69 vs 62SBRA +7
- Value31 vs 25SBRA +6
- Quality48 vs 44SBRA +4
3 of 6 evidence groups favor SBRA. SBRA’s edge is concentrated in momentum and risk resilience.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum +1
No new signals fired.
Largest factor move: Momentum -3
No new signals fired.
SBRA's lead widened by 1 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — SBRA and WELL both carry a full feed there.
The central trade-off
SBRA (Sabra Health Care REIT, Inc.): the stronger current systematic profile, led by momentum and risk resilience.
WELL (Welltower Inc.): the counter-case, on fundamentals, technicals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
SBRASBRA on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
WELLWELL on combined revenue and EPS growth.
Value
SBRASBRA on the peer-relative Value factor, by 6 points.
Momentum
SBRASBRA on the Momentum factor, by 23 points.
Lower downside
SBRASBRA on Risk Resilience, by 7 points.
Analyst upside
EvenAnalyst targets are level or not covered for both names.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | SBRA | WELL | Note |
|---|---|---|---|
| Implied upside to target | +7.2% | +7.5% | Level |
| Target dispersion | +27.3% | +19.3% | Lower is tighter analyst agreement |
| Consensus | Hold | Buy | Context, not a primary driver |
| Analysts covering | 7 | 13 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor SBRA. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | SBRA | 51 vs 41 |
| Fundamentals | WELLon balance | revenue growth 6.4% vs 7.2%; EPS growth -162.5% vs -67.3%; TTM ROE 2.3% vs 3.1%; gross margin 72.6% vs 38.8%; operating margin 11.8% vs 5.4% — WELL takes 3 of 5 decided legs, not all of them |
| Valuation | SBRA | Value 31 vs 25 |
| Technicals | WELL | Price vs 50-day -0.7% vs -0.9%; vs 200-day 4.7% vs 11.5% |
| Risk Resilience | SBRA | Risk Resilience 69 vs 62 |
| Analyst expectations | Even | Target upside 7.2% vs 7.5% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of SBRA and WELL and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is moderate at 10 points.
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been widening. (supports the conclusion holding)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on SBRA.
How the comparison changed
119 daily snapshots · May 4 – Sep 10SBRA lead: Strengthening — the AIQ differential moved from 3 to 10 points over 30 sessions.
- Today
- SBRA +10
- 51 vs 41
- 7 sessions ago
- SBRA +9
- 51 vs 42
- 30 sessions ago
- SBRA +3
- 47 vs 44
- 90 sessions ago
- SBRA +3
- 53 vs 50
The lead changed hands 4 times in this window, most recently on Jul 7 when SBRA moved ahead of WELL.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
4 bullish / 0 bearish / 1 neutral
- Golden Cross Active — bullish, trend, long horizon (3.94%)
- Bollinger Band Squeeze — neutral, volatility, short horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
2 bullish / 1 bearish, conflicted
- Golden Cross Active — bullish, trend, long horizon (12.37%)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- MACD Bearish Crossover — bearish, momentum, short horizon
WELL is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.49%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.04%, AIQ -1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1WELL closes the Momentum gap — currently 23 points behind, the largest single contributor to SBRA's edge.
- 2WELL's MACD Bearish Crossover resolves — a bearish momentum rule currently active against it.
- 3SBRA's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
WELL leads on balance| Metric | SBRA | WELL |
|---|---|---|
| Revenue growth (YoY) | 6.4% | 7.2% |
| EPS growth (YoY) | -162.5% | -67.3% |
| Gross margin | 72.6% | 38.8% |
| Operating margin | 11.8% | 5.4% |
| Return on equity (TTM) | 2.3% | 3.1% |
| Debt to equity | 0.96 | 0.42 |
Performance
WELL leads 4 of 6 windows| Metric | SBRA | WELL |
|---|---|---|
| 1 week (5 sessions) | -0.1% | -1.2% |
| 1 month (20 sessions) | 3.2% | 2.4% |
| 3 months (63 sessions) | 10.7% | 11.5% |
| 6 months (126 sessions) | 0.9% | 14.8% |
| Year to date | 10% | 27% |
| 1 year (252 sessions) | 8.5% | 39.2% |
Technicals
WELL has the stronger structure| Metric | SBRA | WELL |
|---|---|---|
| RSI (14) | 56.5 | 46.7 |
| ADX (14) | 10.2 | 12.1 |
| Price vs 50-day | -0.7% | -0.9% |
| Price vs 200-day | 4.7% | 11.5% |
| Volatility (1M, annualized) | 15.2% | 14.5% |
Risk
SBRA is the more resilient| Metric | SBRA | WELL |
|---|---|---|
| Beta | -0.21 | -0.02 |
| Sharpe ratio | 0.32 | 1.42 |
| Sortino ratio | 0.57 | 2.1 |
| Max drawdown | -16.6% | -12.6% |
| Current drawdown | -7% | -6.5% |
| Annualized volatility | 24.1% | 22.7% |
| Value at risk (95%) | -2.4% | -2.2% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, SBRA or WELL?
On the Algovestiq AIQ Score, SBRA is the stronger of the two as of Sep 11, 2026, scoring 51 against WELL's 41. The edge comes from momentum and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is SBRA or WELL the better buy right now?
SBRA carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Competitive — 3 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor SBRA over WELL?
The composite weights Quality, Value, Momentum and Risk Resilience. SBRA leads Momentum by 23 points; SBRA leads Risk Resilience by 7 points; SBRA leads Value by 6 points. SBRA leads on all four AIQ factor dimensions. Value is itself one of those four, so the sweep is not explained by WELL simply being cheaper — it warrants extra scrutiny for unmodeled catalysts, forward expectations or event risk the factors do not capture.
Which has more analyst upside, SBRA or WELL?
Analyst price targets imply +7.2% upside for SBRA and +7.5% for WELL. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, SBRA or WELL?
SBRA is the better-valued of the two on the peer-relative Value factor. SBRA on the peer-relative Value factor, by 6 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, SBRA or WELL?
WELL on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, SBRA or WELL?
SBRA on the Momentum factor, by 23 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, SBRA or WELL?
SBRA is the more resilient of the two, so the other name carries the higher downside risk. SBRA on Risk Resilience, by 7 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is SBRA more profitable than WELL?
The profitability evidence is mixed: gross margin 72.6% vs 38.8%; operating margin 11.8% vs 5.4%; ttm roe 2.3% vs 3.1%. SBRA leads on two measures and WELL on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is SBRA's lead over WELL getting stronger or weaker?
SBRA lead: Strengthening — the AIQ differential moved from 3 to 10 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands 4 times in that window, most recently on 2026-07-07, when SBRA moved ahead of WELL.
What would change the SBRA vs WELL verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: WELL closes the Momentum gap — currently 23 points behind, the largest single contributor to SBRA's edge; WELL's MACD Bearish Crossover resolves — a bearish momentum rule currently active against it; SBRA's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about SBRA and WELL?
SBRA: 4 bullish / 0 bearish / 1 neutral. WELL: 2 bullish / 1 bearish, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on SBRA is Golden Cross Active (bullish, long horizon). On WELL it is Golden Cross Active (bullish, long horizon).
Compare SBRA and WELL with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.